- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Authors
Keywords
-
Journal
Future Oncology
Volume 7, Issue 10, Pages 1149-1167
Publisher
Future Medicine Ltd
Online
2011-10-12
DOI
10.2217/fon.11.95
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract C60: In vitro efficacy of the dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in hepatocellular carcinoma
- (2012) E. I. Buchbinder et al. MOLECULAR CANCER THERAPEUTICS
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies
- (2011) Shinji Tanaka et al. JOURNAL OF GASTROENTEROLOGY
- Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
- (2011) K.-F. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Pilot study: rapamycin in advanced hepatocellular carcinoma
- (2010) M. Schöniger-Hekele et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma
- (2010) Andreas A Schnitzbauer et al. BMC CANCER
- Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells
- (2010) Xinxin Bu et al. CANCER BIOLOGY & THERAPY
- Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung
- (2010) Donatella Malanga et al. CELL CYCLE
- Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma
- (2010) Higinia R. Cárdenes et al. Clinical & Translational Oncology
- IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage
- (2010) Victoria Tovar et al. JOURNAL OF HEPATOLOGY
- Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains
- (2010) B. Miao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel
- (2009) C. Sessa et al. ANNALS OF ONCOLOGY
- A novel regulatory event-based gene set analysis method for exploring global functional changes in heterogeneous genomic data sets
- (2009) Chien-Yi Tung et al. BMC GENOMICS
- Novel Agents on the Horizon for Cancer Therapy
- (2009) W. W. Ma et al. CA-A CANCER JOURNAL FOR CLINICIANS
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms
- (2009) E.A. Dunlop et al. CELLULAR SIGNALLING
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study
- (2009) Lars M. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
- (2009) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
- (2009) Sean F. Altekruse et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
- (2009) Antonio Jimeno et al. JOURNAL OF CLINICAL ONCOLOGY
- The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
- (2009) Ledu Zhou et al. MEDICAL ONCOLOGY
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Radiotherapy for Hepatocellular Carcinoma: An Overview
- (2008) Sunil Krishnan et al. ANNALS OF SURGICAL ONCOLOGY
- Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma
- (2008) Ka Ho Tam et al. CANCER LETTERS
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer
- (2008) P. C. Manegold et al. CLINICAL CANCER RESEARCH
- Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma
- (2008) Z. Wang et al. CLINICAL CANCER RESEARCH
- Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
- (2008) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- E2F1 Inhibits c-Myc-Driven Apoptosis via PIK3CA/Akt/mTOR and COX-2 in a Mouse Model of Human Liver Cancer
- (2008) Sara Ladu et al. GASTROENTEROLOGY
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
- Molecular targeted therapies in hepatocellular carcinoma
- (2008) Josep M. Llovet et al. HEPATOLOGY
- Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma
- (2008) Anne-Christine Piguet et al. JOURNAL OF HEPATOLOGY
- Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells
- (2008) Konstantinos G. Lasithiotakis et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- AKT1 E17K in human solid tumours
- (2008) F E Bleeker et al. ONCOGENE
- The p110 isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110
- (2008) J. Guillermet-Guibert et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis
- (2008) Asmaa Ibrahim Gomaa et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
- (2008) Tim F Cloughesy et al. PLOS MEDICINE
- Targeting phosphoinositide 3-kinase—Moving towards therapy
- (2007) Romina Marone et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started